Sector Experts

Subscribe to
Streetwise Reports

Ask this Expert

Companies Commented On

  • Aastrom Biosciences Inc.
  • BioBlast Pharma
  • Celator Pharmaceuticals
  • Celldex Therapeutics Inc.
  • Concert Pharmaceuticals
  • Curis Inc.
  • Cytokinetics Inc.
  • Cytori Therapeutics Inc.
  • Dendreon Corp.
  • Galena Biopharma Inc.
  • GenVec Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Isis Pharmaceuticals Inc.
  • Lion Biotechnologies Inc.
  • Lorus Therapeutics
  • MEI Pharma Inc.
  • Palatin Technologies Inc.
  • Peregrine Pharmaceuticals Inc.
  • Pharmacyclics Inc.
  • Regeneron Pharmaceuticals Inc.
  • Rexahn Pharmaceuticals Inc.
  • Roche Holding AG
  • Spectrum Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Synta Pharmaceuticals Corp.
  • Teva Pharmaceutical Industries Ltd.
  • TG Therapeutics Inc.
  • Verastem Inc.

Joseph Pantginis

ROTH Capital Partners

Image: Joseph  Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JbHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.




Recent Interviews

Shortage of R&D at Big Pharma Creates Demand for Small Biotech: Joseph Pantginis (6/5/14) The recent pullback in biotech shares has not changed the time-tested theory of investing in small-cap drug development companies. Good or bad data will continue to move shares. In this interview with The Life Sciences Report, ROTH Capital Partners' Senior Research Analyst Joseph Pantginis presents five biotech names with varying timeframes for market-moving data that could provide huge upside for investors willing to do some homework and understand the growth proposition.

Seven Investments on Biotech's Cutting Edge: Joseph Pantginis (11/14/13) Phase 1 and phase 2 biotech companies offer great upside for investors who understand the risks and the critical need for diversification. ROTH Capital Partners Senior Research Analyst Joseph Pantginis has staked out a basket of small-cap oncology biotech names with cutting-edge technology platforms that have realistic opportunities for success. In this interview with The Life Sciences Report, Pantginis makes meticulous arguments for seven names that offer huge upside.

Recent Quotes

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer." (9/24/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as a ground floor opportunity." (8/14/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"The RNN story can now be viewed as an emerging opportunity." (7/18/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"RNN's RX-3117 has potential to be a sleeper product candidate." (6/5/14) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M." (6/5/14) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

"We initiate coverage on RNN with a Buy rating." (1/9/14) Rexahn Pharmaceuticals Inc. - Joseph Pantginis, ROTH Capital Partners More >

"Japan's new Regenerative Medicine Law is positive for CYTX." (11/21/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX's upcoming ATHENA clinical data will be a major catalyst for the company, giving confidence not only to investors but also to the physician community." (11/14/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Joseph Pantginis More >

more comments

"We are encouraged by CYTR's preliminary response data for the first-line sarcoma study." (9/30/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is a leading regenerative medicine player." (9/20/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"CYTX is poised for significant cash flow and its cardiovascular pipeline holds promise." (9/10/13) Cytori Therapeutics Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We maintain our Buy rating on CYTR; investors should own shares." (8/6/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We believe that IMUC is well positioned to become a leading player in the cancer immunotherapy space." (7/30/13) ImmunoCellular Therapeutics Ltd. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on CYTR." (6/24/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"We reinstate our Buy rating on CYTR." (5/31/13) CytRx Corp. - Joseph Pantginis, ROTH Capital Partners More >

"GALE is well positioned for a successful outcome of the phase 3 NeuVax PRESENT study." (5/10/13) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We are encouraged by Teva's excitement for GALE's NeuVax program." (12/4/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"We reiterate our Buy rating on GALE." (11/13/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

"GALE's new data supports our view for a positive outcome to the phase 3 PRESENT study." (10/29/12) Galena Biopharma Inc. - Joseph Pantginis, ROTH Capital Partners More >

fewer comments


Due to permission requirements, not all quotes are shown.